Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials A Secondary Analysis of 3 Randomized Clinical Trials

摘要

IMPORTANCE The US Food and Drug Administration recognizes total abstinence and no heavy drinking days as outcomes for pivotal pharmacotherapy trials for alcohol use disorder (AUD). Many patients have difficulty achieving these outcomes, which can discourage seeking treatment and has slowed the development of medications that affect alcohol use.